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Abstract
Background: Retinoids are very potent inducers of cellular differentiation and apoptosis, and are
efficient anti-tumoral agents. Synthetic retinoids are designed to restrict their toxicity and side
effects, mostly by increasing their selectivity toward each isotype of retinoic acids receptors
(RARα ,β , γ  and RXRα , β , γ ). We however previously showed that retinoids displayed very different
abilities to activate retinoid-inducible reporter genes, and that these differential properties were
correlated to the ability of a given ligand to promote SRC-1 recruitment by DNA-bound RXR:RAR
heterodimers. This suggested that gene-selective modulation could be achieved by structurally
distinct retinoids.
Results: Using the differential display mRNA technique, we identified several genes on the basis of
their differential induction by natural or synthetic retinoids in human cervix adenocarcinoma cells.
Furthermore, this differential ability to regulate promoter activities was also observed in murine
P19 cells for the RARβ 2 and CRABPII gene, showing conclusively that retinoid structure has a
dramatic impact on the regulation of endogenous genes.
Conclusions: Our findings therefore show that some degree of selective induction or repression
of gene expression may be achieved when using appropriately designed ligands for retinoic acid
receptors, extending the concept of selective modulators from estrogen and peroxisome
proliferator activated receptors to the class of retinoid receptors.
Background
Retinoic acids exert profound effects on cellular differen-
tiation and proliferation. In many cases, retinoids display
anti-tumoral activities [1,2] which are characterized by a
retinoid-induced cell cycle arrest in the G0/G1 transition
phase [3] These biological properties are either due to
transcriptional upregulation of target genes through a well
defined mechanism [reviewed in [4]] or/and mediated
through the ability of retinoids to interfere with the acti-
vation of transcription factors controlling proliferative re-
sponses of cells to mitogenic stimuli such as AP-1.
Transcriptional activation by retinoids is mediated
through two families of nuclear receptors, all-trans retino-
ic acid (RARs) and 9-cis retinoic acid receptors (RXRs),
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whereas interference with AP-1 is likely to be due to the
inhibition of signalling pathways controlled by mem-
brane receptors [5,6] or to protein:protein interactions
[7,8] Modification of the all-trans retinoic acid structure to
improve the specificity and/or the potency of naturally oc-
curing molecules led to the synthesis of a number of com-
pounds characterized by the cyclization of the polyenic
chain of all-trans retinoic acid and the addition of various
groups at different positions. These conformationally re-
stricted retinoids are now used to achieve selective activa-
tion of RAR isotypes α , β  or γ  in-vitro and in-vivo, which
reduces side-effects in therapeutical applications. Synthet-
ic retinoids mimic some of all-trans retinoic acid biologi-
cal effects in-vivo, but interact differently with the ligand
binding domain of RARα  and induce distinct structural
transitions of the receptor [9,10]. We have demonstrated
that RAR-selective ligands have distinct quantitative acti-
vation properties which are reflected by their ability to
promote interaction of DNA-bound hRXRα /hRARα  het-
erodimers with the nuclear receptor coactivator (NCoA)
SRC-1in-vitro[11] The hormone response element core
motifs spacing has a determining influence of RXR:RAR
DNA-binding activity, by defining the relative affinity of
liganded heterodimers for NCoAs. hRXRα  AF2 was critical
to confer hRARα  full responsiveness, but not differential
sensitivity of hRARα  to natural or synthetic retinoids.
These findings suggested that the use of physically distinct
NCoA binding interfaces may be important in controlling
specific genes by conformationally restricted ligands and
may affect the overall activity of synthetic retinoids vs nat-
ural molecules.
Previous studies have demonstrated that synthetic retin-
oids can not only be isotype-selective, but also display a
certain degree of selectivity toward defined receptor-RARE
combinations [12,13]. The role of the ligand structure is
emphasized by our recent observations [11], which sug-
gested that further refinement in gene selectivity could be
achieved by altering NCoA interaction surfaces. Selective
recruitment of p300 or CBP has indeed been shown to be
required for selective activation of p21Cip1 and of p27Kip1
genes respectively [14]. Since transcriptional activation is
the end result of multiple interactions between the recep-
tor, its dimerization partner, DNA and ligand, one may
speculate that conformationally restricted retinoids with
highly selective biological activities may be designed. Be-
side the tremendous interest for therapeutical applica-
tions, this raised the possibility that such retinoids display
distinctive abilities to activate endogenous target genes.
To further test this hypothesis, we have used the differen-
tial display technique as described by Liang and Pardee
[15] to investigate the differential regulation of genes by
natural and synthetic retinoids in a human cervical carci-
noma cell line (HeLa). A first screening allowed to isolate
and to clone 140 ESTs that were differentially induced or
repressed by retinoids. In this paper, we report the charac-
terization of two genes which are down-regulated by retin-
oids, and show that differential regulation is observed in
different cell types.
Results
Expression of retinoic acid receptors and of nuclear core-
pressors and coactivators in HeLa cells
HeLa cells are known to express low levels of endogenous
all-trans (RARs), 9-cis retinoic acid receptors (RXRs) and
nuclear coactivators and corepressors. However, relative
levels of expression of these proteins have not been mon-
itored in this cell line and thus a comprehensive study was
carried out to characterize mRNA levels coding for each
protein. Using RT-PCR amplification of specific tran-
scripts from total RNA, we observed that hRARα , hRXRα
and hRXRβ  were predominantly expressed in this cell line
(Figure 1A). Using nested PCR primers, trace amounts of
hRARβ  were detected (Figure 1B), whereas hRARγ  and
hRXRγ  were not detectable in these conditions (note that
amplification products in the corresponding lanes are non
specific amplification products and did not match the pre-
dicted size of amplified cDNA). We then assayed similarly
expression levels for nuclear coactivators AIB1 [16], CBP
[17], p300 [18], p/CIP [19], RAC3 [20], RIP140 [21],
SRC1 [22], TIF1 [23], TIF2 [24] and TRIP1 [25]. As shown
in Figure 1C, each coactivator mRNA was detectable in
HeLa cells, and we also observed by Western blot analysis
that members of the DRIP/TRAP coactivator family [26]
are also expressed in this cell line (see panel E). Expression
levels of nuclear corepressors N-CoR [27] and SMRT [28]
were also assessed (Figure 1D). Among these two core-
pressors, only SMRT/TRAC2 was found to be significantly
expressed. Two amplification products were character-
ized, reflecting the occurrence of two transcripts of SMRT
as described previously [29].
Thus HeLa cells express most of coactivators described so
far, and SMRT was found to be expressed at significant lev-
els. Retinoic acid receptors hRARα , hRXRα  and hRXRβ
were predominantly expressed, with trace amounts of
hRARβ . We note that the expression of this receptor was
barely inducible upon atRA treatment (data not shown),
suggesting that cell-specific features may condition the re-
sponsiveness of endogenous genes to retinoids. However,
we also observed that transiently transfected reporter
genes bearing consensus retinoic acid response elements
(RARE) are fully inducible in this cell line [11], raising the
possibility that chromatin assembly on DNA templates
strongly regulates retinoid responsiveness [30]. The ex-
pression level of SMRT and of several coactivators was also
confirmed by western blot analysis of HeLa whole cell ex-
tracts (Figure 1E). This analysis confirmed that most of
coactivators are coexpressed in this cell line, as well as veryBMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/13
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Figure 1
Expression levels of retinoic acid receptors and of transcriptional intermediary factors in HeLa cells. HeLa cells mRNA was extracted
and analyzed by RT-PCR using specific primers to detect (A) hRARα , hRARβ , hRARγ , hRXRα , hRXRβ  and hRXRγ  transcripts;
to confirm the lack of expression of hRARβ , hRARγ  and hRXRγ  by nested PCR (B) to characterize expression levels of nuclear
coactivators (C) and nuclear corepressors (D). E) Western blot analysis of HeLa whole cell extracts. 100 µg of proteins were
resolved by 8% SDS-PAGE and blotted onto a nitrocellulose membrane. This membrane was probed with antibodies specific
for each indicated receptors, coactivators or corepressor. The left panel shows a silver-stained gel on which 10 µg of cell
extract has been separated. Molecular masses are indicated in kDa.
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low amount of RARα  and detectable amounts of RXRs
(available antibodies are not isotype-selective).
Identification of genes differentially expressed in response 
to retinoid treatment
Thus modulation of gene expression by RAR-specific
retinoids may be expected to be mostly dependent upon
ligand binding to hRARα  and dimerization with either
RXRα  or RXRβ
Total RNA was then extracted from HeLa cells treated for
4 hours with 1µM atRA, our reference compound, 1µM
CD3106/AGN 193109, a RAR-specific antagonist [31],
1µM TTNPB and 20 nM Am580, two synthetic RARα -spe-
cific agonists, 1µM CD367, a RAR-specific agonist [32]
and 1µM CD2425, a RXR-specific retinoid. mRNAs were
then randomly amplified using various combinations of
oligodT anchored primers (see legend to figure 2 for more
details) and arbitrary chosen primers in the presence of α -
[33P]-labelled dATP. Products were visualized by autora-
diography of high resolution sequencing gels. Examina-
tion of autoradiographies allowed the identification of
several mRNAs species that were specifically induced
upon treatment with some of the retinoids described
above. Typical results are shown in Figure 2 for four differ-
ent sets of primers which allowed the amplification of dif-
ferentially expressed genes. This differential expression
was noted for about 60% of the primer sets, while others
did not show any significant variations. Based on visual
examination of 40 sequencing gels, cDNAs were extracted
from the gel, reamplified by PCR using the same set of
primers than that used in the initial RT-PCR reaction,
cloned in the PCR-Trap vector by T/A cloning, and se-
quenced. 140 cDNAs were identified (hereafter noted syn-
thetic retinoid-induced genes or SRIG) following this
procedure and could be classified into three categories: (i)
sequences with no homology with any known human
genes; (ii) sequences overlapping with previously identi-
fied ESTs and (iii) sequences homologous to genes with
known function(s). These results are summarized in Table
1 and Table 2. 28 new ESTs were identifed and sequences
were deposited in GenBank.
To further validate our initial screening, probes ranging in
size from 200 to 350 bp were obtained by PCR using
primers flanking the insertion site of the cDNA. 96 probes
were thus synthesized, spotted onto a nylon membrane to
generate cDNAs arrays. Total RNAs extracted from HeLa
cells treated for 4 hours by the indicated retinoid (see Fig-
ure 3) was reverse-transcribed in the presence of α -[32P]
dCTP and hybridized to membranes. Twenty genes
showed marked differential regulation in this secondary
screening, exhibiting various pharmacological profiles
(data not shown). Of interest were genes found to be in-
duced upon treatment with the RAR antagonist CD3106
(SRIG 61, 62 and 150). Two genes were repressed upon
atRA treatment, but induced in the presence of other syn-
thetic agonists (SRIG 146 and 177) and three were activat-
ed to various extent by retinoid agonists (SRIG 126, 148,
169). Other genes followed a more complex pattern
which does not match a simple relationship between RAR
transcriptional activation, pharmacological properties of
retinoids and gene expression levels, reflecting a likely in-
volvement of multiple, retinoid-induced steps in gene reg-
ulation.
Characterization of genes differentially regulated in re-
sponse to retinoid treatment
Search against EMBL/GenBank databases using the Blast
server identified the human initiation factor 4B (hIF4B,
SRIG 69), human apoferritin H (SRIG 157) and human
TAXREB 107 (SRIG 177). We also noted that the human
plasminogen activator was identified in this screen, which
is a gene known to be activated by retinoids [33], as well
as the ubiquitin conjugating enzyme UCE, which was
identified recently by a similar approach as an atRA-in-
ducible gene in acute promyelocytic leukemia (APL) cells
[33,34]. Northern blot analysis of HeLa cells RNA was
thus used to assay the rate of expression of several genes
after retinoid treatment and results are shown for ferritin
H and TAXREB 107 (Figure 3 and 4).
Homeostasis of iron is mostly dependent on two cellular
proteins, ferritins H and L. Ferritin L has been shown to be
regulated in HeLa cells by iron, while ferritin H is not reg-
ulated by this metal [35]. Northern blot analysis of HeLa
cells RNA showed that the SRIG 157 clone, identified as
ferritin H in our screen, was clearly down-regulated (Fig-
ure 3) by some retinoids. The most active were Am580,
CD367, and the RXR-selective ligand CD2425. Thus these
retinoids, which do not share receptor binding properties,
repressed apoferritin H expression, in contrast to atRA
which was inactive in this test.
TAXREB107 binds to tax-responsive elements and thus
have functions in the context of HIV infection, by mediat-
ing the DNA binding of the HTLV-1 transactivator Tax. It
was also identified as a ribosomal protein, and we noted
that the ribosomal protein L27a was also identified sever-
al times in our screening procedure (Table 2 and data not
shown). Again, this mRNA was submitted to a reproduci-
ble, selective down-regulation in the presence of TTNPB,
CD367 and CD2425 (Figure 4). Thus although no predic-
tion could be drawn from the selectivity of a given ligand
for a RAR isotype, this result establishes again that retin-
oids have distinct abilities to modulate the rate of expres-
sion of several cellular genes.BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/13
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Figure 2
Differential expression of mRNA species in HeLa cells treated by retinoids. Differential display RT-PCR analysis of HeLa tran-
scripts obtained from cells treated with 1µM of the indicated retinoid for 4 hours. Total RNA was extracted and purified from
HeLa cells and reverse-transcribed with the H-T11G (AAGCT11G, left panel), H-T11A (AAGCT11A, middle panel) or H-T11C
(AAGCT11C, right panel) primers. PCR amplification of cDNAs was carried out using the same 3' primer and the H-AP3
primer (AAGCTTTGGTCAG), the H-AP6 primer (AAGCTTGCACCAT), the H-AP12 primer (AAGCTTGAGTGCT) and the
H-AP15 primer (AAGCTTACGCAAC) (from left to right) in the presence of α -[33P] dATP. Amplified cDNA fragments were
analyzed on 6% sequencing gels and visualized by autoradiography. Typical lanes are shown, with size markers appearing on the
left. Selectively regulated mRNAs are indicated by dots. These materials were extracted from the gel, re-amplified by PCR with
the same set of primers, cloned into the pCR-TRAP vector (GenHunter) and sequenced.BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/13
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Table 1: Summary of newly identified ESTs and of known ESTs potentially regulated by retinoids.
A) New sequences
Name Homology GenBank Accession Numbers Northern
SRIG 23*, SRIG 28*, SRIG 33.1*, SRIG 53*, SRIG 56*, SRIG 61, 
SRIG 74, SRIG 81, SRIG 86, SRIG 89, SRIG 90, SRIG 102, SRIG 
105, SRIG 107, SRIG 118*, SRIG 119, SRIG 124, SRIG 131, SRIG 
144, SRIG 145, SRIG 148, SRIG 154, SRIG 160, SRIG 164, SRIG 
178, SRIG 179, SRIG 181, SRIG 185-1.
No significant homol-
ogy
AI374463*, AI374461*, AI374438*, 
AI376338*, AI374462*, AI374456, 
AI374464, AI374455, AI376315, 
AI374453, AI37441, AI374452, 
AI374451, AI374450, AI374449*, 
AI374448, AI374447, AI374446, 
AI376322, AI376323, AI376324, 
AI374443, AF096777, AI376330, 
AI374465, AI376335, AI374444, 
AI374445
No signal*, 
other clones 
were not 
tested.
B) Identified ESTs
SRIG 8 100% with EST 
AA931835
AI376308 (Unigene Hs 181165) No signal
SRIG 29 100% with EST 
AA027854
AI376309 (Unigene Hs 8117) No signal
SRIG 30 100% with EST 
AA534569
AI376310 (Unigene Hs 13836) No signal
SRIG-62 100% with KIAA0043 
gene
SRIG 63 74% with EST 
AA699895
AI376312 (Unigene Hs 117353) N.D.
SRIG 67 90% with EST 
AA826918
AI376313 N.D.
SRIG 80 89% with EST 
AA568770
AI376314 N.D.
SRIG 100 97% with EST R02820 AI376317 (Unigene Hs 31921) N.D.
SRIG 101 99% with EST 
AA449652
AI376318 (Unigene Hs 11803) N.D.
SRIG 108 80% with EST 
AA205076
AI374442 (Unigene Hs 17872) N.D.
SRIG 123 94% with EST C75518 AI376319 (Unigene Hs 61184) N.D.
SRIG 134 96% with EST 
AA983976
AI376320 (Unigene Hs 127105) N.D.
SRIG 135 96% with EST 
AA093075
AI376321 (Unigene Hs 49015) N.D.
SRIG 150 100% with EST 
AA768579
AI376326 (Unigene Hs 22549) N.D.
SRIG 153 97% with EST 
AA768579
AI376327 (Unigene Hs 112227) N.D.
SRIG 156 100% with EST 
AA505468
AI376329 (Unigene Hs 58609) N.D.
SRIG 165 99% with EST 
AI097038
AI376331 (Unigene Hs 156103) N.D.
SRIG 173 99% with EST 
AA838424
AI376333 (Unigene Hs 110978) N.D.
A) Sequences were searched against GenBank and no significant homologies were found. Sequences were deposited in GenBank and accession 
numbers are indicated. B) Identification of previously identified ESTs as potential targets for retinoid modulation. GenBank accession numbers are 
given, as well as the Unigene family number. ND: not determined.BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/13
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The RARβ 2 and CRABPII promoters respond differentially 
to retinoids in murine embryonal carcinoma cells
Murine pluripotent P19 cells can differentiate into endo-
dermal and mesodermal cells after retinoic acid treatment
(reviewed in [36]) and have a number of characteristics
which make them suitable for analysis of RA-mediated
gene induction [37]. Retinoic acids receptors RARα , RARγ
and RXRγ  are constitutively expressed in this cell line (data
not shown), whereas RARβ  is induced upon atRA treat-
ment (Figure 5A). The cellular retinoic acid binding pro-
tein type II (CRABPII) gene expression is also regulated by
retinoids (Figure 5B and [38]). To further investigate the
possibility that retinoids have differential abilities to stim-
ulate gene expression in a similar cellular background, we
monitored RARβ  and CRABPII expression by Northern
blotting and RT-PCR upon stimulation by limited concen-
trations (2x Kd) of several natural or synthetic retinoids.
atRA turned out to be a good inducer of the RARβ  promot-
er, with transcripts becoming detectable after 4 hours of
induction. mRNA accumulation reached a plateau after 8–
10 hours of induction, after which a clear, specific down-
regulation was observed. (Figure 5A). Other retinoids
could be distinguished on the basis of the rate of induc-
tion and of their efficiencies to promote RARβ  mRNA ac-
cumulation. TTNPB was a strong inducer in our system, as
well as CD367. Am580 caused a time course of mRNA ac-
cumulation slower when compared to that observed with
atRA and other retinoids, and yielded maximal mRNA lev-
els increased by 3-fold when compared to atRA. The
CRABPII gene transcriptional regulation by retinoids ex-
hibited a very different time-course, characterzed by a very
s l o w  a c c u m u l a t i o n  o f  m R N A  a t  e a r l y  t i m e  p o i n t s  ( < 8
hours) with synthetic retinoids (Figure 5B). atRA, on the
contrary, induced a moderate but rapid induction of the
CRABPII mRNA synthesis, reaching a plateau in less than
8 hours, whereas all other agonists were weak inducers at
early time points, and were much more potent at 24 and
48 hours.
Table 2: Summary of genes with known functions as potential targets for retinoid modulation.
Name Homology Northern
SRIG 1 100% homology with ZNF beta No signal
SRIG 14 99% homology with human ribosomal protein L27a N.D.
SRIG 15 98% homology with human nuclear protein 55 No differential regulation
SRIG 16 100% homology with human fibrilline-2 No signal
SRIG 19 100% homology with cytochrome oxydase II No differential regulation
SRIG 24 100% homology with human ubiquitin conjugating enzyme No differential regulation
SRIG 45 100% homology with human thymidilate synthase No differential regulation
SRIG 52 91% homology with human phosphate cyclase No signal
SRIG 62 Brd3-human bromodomain-containing protein 3 (RING3-like protein) N.D.
SRIG 69 97% homology with human initiation factor 4B Differential regulation
SRIG 71' 77% homology with human spermine/spermidine acetyl transferase N.D.
SRIG 76 97% homology with human 5T4 oncofetal antigen No signal
SRIG 93 98% homology with human histone H2B.2 No differential regulation
SRIG 96 79% homology with human TRIP7 No signal
SRIG 106 99% homology with epilepsy holoproencephaly candidate protein-1 No signal
SRIG 112 97% avec protein phosphatase No signal
SRIG 113 97% with human NaCl electroneutral thiazide-sensitive transporter No signal
SRIG 114 98% human 60S ribosomal protein N.D.
SRIG 120 99% homology with EST similar to human TRAM protein N.D.
SRIG 121 98% homology with human aspartyl beta hydroxylase N.D.
SRIG 126 100% with human protein kinase C binding protein Nel No signal
SRIG 128 96% homology with human enolase N.D.
SRIG 142 85%homology with human carbamyl phosphate synthase No signal
SRIG 157 95% homology with human apoferritine H Differential regulation
SRIG 158 99% homology with human cytochrome B No differential regulation
SRIG 165' 96% homology with human CG1 No signal
SRIG 169 100% homology with human duplicate spinal muscular atrophy N.D.
SRIG 174 99% homology with spermidine acyl transferase No signal
SRIG 177 99% homology with human TAXREB 107 Differential regulation
SRIG 185-2 98% homology with human plasminogen activator N.D.
Sequences were identified according to their homology with previously identified genes. The degree of homology is indicated for each mRNA, as 
well as the name of the gene. Northern blot analysis results are indicated when available. ND: not determined.BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/13
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Ranking of retinoids for their potency is therefore similar
when assessing both RARβ 2 and CRABPII mRNA accumu-
lation at 48 hours (TTNPB>CD367>Am580>atRA). How-
ever, this order of potency may considerably vary when
Figure 3
Expression of ferritin H mRNA in HeLa cells treated with different ligands of the retinoic acid receptor. HeLa cells were
treated with the different ligands for four hours. Total RNA (20 µg) was probed sequentially with fluorescein-labeled partial
human ferritin H cDNA and 18S rRNA probes. Blots were quantified using a Storm™ apparatus. Values for the ferritin H tran-
script were normalized to the 18S rRNA level. A) Upper panel: ferritin H transcript in HeLa cells treated with various retinoids.
Lower panel: 18S rRNA. B) Quantification of ferritin H expression. Results are presented as the mean +/- S.E.M. of three differ-
ent experiments. Cells were treated with 25nM atRA, 30nM CD3106, 80nM TTNPB, 20 nM Am580, 10nM CD367 and 100nM
CD2425 for 4 hours.
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considering earlier time points: a 2-hours induction, more
likely to reflect transcriptional processes, yields the fol-
lowing ranking for the RARβ 2 gene: CD367>at-
RA>TTNPB>Am580, and a 8-hours induction for the
CRABPII gene gives the following ranking: at-
RA>CD367>TTNBP=Am580.
Figure 4
Expression of TAXREB107 mRNA in HeLa cells treated with different ligands of the retinoic acid receptor. HeLa cells were
treated with the different ligands for 4 hours. Total RNA (20 µg) was probed sequentially with fluorescein-labeled partial
human TAXREB cDNA and 18S rRNA probes. Blots were quantified using a Storm™ apparatus. Values for the TAXREB tran-
script were normalized to the 18S rRNA level. A) Upper panel: TAXREB107 transcript in HeLa cells treated with various retin-
oids. Lower panel: 18S rRNA. B) Quantification of TAXREB107 expression. Results are presented as the mean +/- S.E.M. of
three different experiments. Retinoid concentrations were as in Figure 3.
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Figure 5
Expression of RARβ  and of CRABPII in murine P19 cells treated with different ligands of the retinoic acid receptor. A) Time-
course analysis of RARβ  transcripts. RARβ  transcripts were assayed by Northern blotting (upper panel) and quantified by den-
sitometry. A more rigorous measurement of each time point was carried out by submitting the same sample to real time PCR
quantification, using, as for the Northern blot analysis, 18S RNA as an internal standard. All results are expressed relative to
RARβ  level of expression in non stimulated cells. Representative autoradiograms and PCR quantification are shown here, but
have carried out 3 times with similar results. B) Time-course analysis of CRABPII transcripts. Assays were carried out as
described in A), setting the reference (non stimulated cells) to 100%. Retinoid concentrations were as in Figure 3.
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Discussion
Pursuant to our discovery that natural and synthetic retin-
oids possess distinct abilities to activate a reporter gene in
an identical cellular background, and irrespective of their
affinity for their cognate receptor [11], we set up a differ-
ential display approach to extend this observation to the
regulation of chromatin-organized, endogenous genes.
Selective induction or repression of tens of mRNAs species
was observed during the initial screening, revealing that
genes involved in multiple aspects of cellular regulation
could be potentially regulated specifically by one or sever-
al retinoids. Only a few genes are known to be regulated
by retinoids, and identification of new targets for these
molecules is critical for a better understanding of the phar-
macology of retinoids.
As stated by a number of investigators, the mRNA differ-
ential display method yields false positives and also iden-
tified cDNAs which were not detectable by northern
blotting. However, it is worth noting that we restricted our
study to genes that are induced very early by retinoids by
using induction times of 4 hours, and this may be an ex-
planation for not reaching an intracellular concentration
allowing further detection. In addition, intracellular retin-
oid uptake and metabolic transformation of each com-
pound may vary, and thus introduce variations which are
not related directly to transcriptional regulation. Indeed,
retinoid-regulated genes follow various kinetics of induc-
tion and reaching a steady state may necessitate up to 24–
48 hours in P19 cells, as noted very clearly for the CRAB-
PII gene ([39] and Figure 5). Within this cellular context,
we further show that retinoids have also differential abili-
ties to promote both RARβ  and CRABPII gene transcrip-
tion, giving support to our working hypothesis. This
regulation appeared to vary according to the promoter.
Interestingly, we identified several genes that were down-
regulated by retinoids. Apoferritin H and TAXREB107
were clearly inhibited by a specific set of retinoids (40–
50% inhibition), to an extent which is considered to be
highly significant in pathological states. This may also be
relevant in normal conditions, when considering that a
biological response is very likely to be part of an integrat-
ed signaling pathway, in which a decrease of 50% of a giv-
en step may strongly alter the end result of the activation
of this pathway. For example, vascular endothelial growth
factor (VEGF) has been shown to be down-regulated by
retinoids by two-fold in human keratinocytes and this
may be related to the therapeutic effects of retinoids in
diseases such as psoriasis and Kaposi' sarcoma [40].
Retinoids have numerous side effects which severely limit
dosage in clinical trials. They include skin irritation and
inflammation, elevation of serum triglycerides, hypothy-
roidism and others such as headache (reviewed in [41]).
Given the potential of retinoids in treating various disor-
ders such as skin hyperproliferation and photoaging, can-
cer therapy and in metabolic disorders, it is of interest to
identify systematically target genes in altered tissues. Our
approach identified such candidates genes, and the avai-
bility of DNA microarrays and of the human genome se-
quence allows now a genome-wide search of directly or
indirectly regulated genes. Combined with appropriate
structure-activity relationships studies, retinoids define a
very promising field in medicinal chemistry. Used alone
or in combination with other powerful molecules such as
histone deacetylase inhibitors, one may think of achieving
a high degree of selectivity, and thereby reduce toxicity
and other side effects of these promising therapeutic
agents.
Materials and methods
Materials
All-trans retinoic acid was purchased from Sigma (Saint
Quentin Fallavier, France). Synthetic retinoids CD3106,
TTNPB, Am580, CD367 and CD2425 were obtained from
Galderma Inc. (Sophia-Antipolis, France). 10 mM stock
solutions were prepared in DMSO and stored at -20°C in
the dark. Dulbecco's modified Eagle's medium, fetal calf
serum and penicillin/streptomycin mix were purchased
from Biowhittaker (BioWhittaker, Verviers, Belgium). Ol-
igonucleotides were purchased from Eurogentec (Le Sart-
Tilman, Belgium).
RNA preparation
Human HeLa cells were grown in DMEM medium supple-
mented with 10% fetal calf serum and 1000 U/mL of pen-
icillin and 10 µg/mL of streptomycin. Cells were treated
with the indicated retinoic acid receptors ligands for 4
hours. Total RNA was prepared using RNAble reagent (Eu-
robio, Les Ulis, France) according to the manufacturer's
protocol. Total RNA (50 µg) was then treated with 10 U
RNase-free DNaseI (Genhunter, Nashville, TN, USA) for 1
hour at 37°C to digest genomic DNA. The purified RNA
was adjusted to 1 µg/µl and checked for integrity by stand-
ard agarose gel electrophoresis.
Differential display PCR
The differential display reaction was performed using the
RNAimage™ kit as indicated by the manufacturer (Gen-
hunter, Nashville, TN, USA). Briefly, reverse transcription
was performed using 1 µg RNA and an oligodT anchored
primer. The PCR reaction was carried out with the an-
chored oligodT primer used in all possible combinations
with sixteen different arbitrary primers (HAP-1/HAP-16)
in presence of [α -33P]dATP (2000 Ci/mmol, Amersham,
Les Ulis, France). Reactions mixes were submitted to 40
cycles of PCR as follows: 94°C for15 sec, 40°C for 2 min
and 72°C for 30 sec followed by an elongation step at
72°C for 5 min. PCR products were then fractionated on aBMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/13
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8 M urea-6% polyacrylamide gel and visualized by autora-
diography. Differentially expressed cDNAs were extracted,
purified and reamplified under similar PCR conditions
with radioinert deoxyribonucleotides. Amplified cDNAs
were then cloned into the pCR-TRAP vector (Genhunter,
Nashville, TN, USA) as indicated by the manufacturer. The
size of the cloned insert was checked from 3 to 4 colonies
and sequenced. Sequence homologies were established
using Basic Local Alignement Tool against the GenBank
databases. Identified ESTs were then searched against the
UniGene (NCBI) database.
Western-blot analysis
Western blotting and antibodies: Whole cell extracts were
prepared as follows: 5.106 ce ll s  c e l l s  w e r e  gr o w n ,  an d
monolayers were scraped rapidly in ice-cold 1×  Phosphate
Buffered Saline (PBS). Cells were lysed in one volume of
SDS-PAGE loading buffer and briefly sonicated. Western
blotting was carried out as described [11]. The DRIP205,
130 and 150 anti sera were a gift from Drs C. Rachez and
L.P. Freedman. Peroxidase-coupled anti-mouse, anti-goat
or anti-rabbit IgGs were from Sigma. All other antibodies
were purchased from SantaCruz Biotechnology (San-
taCruz, CA.).
Reverse transcription and amplification (RT-PCR) of retin-
oic acid receptors, coactivators and corepressors mRNAs 
in HeLa cells
RNA was extracted and submitted to reverse transcription
as described above. Primers were designed to amplify cD-
NAs fragments ranging in size from 300 to 600 bp and
were as follows: hRARα , 5'-CCATTGAGACCCAGAG-
CAGC-3' and 5'-TGTGTCCATGTGGCGTGGGC-3';
hRARβ , 5'-CAATTGAAACACAGAGCACC-3' and 5'-
CCACCAAGTGGTGACTGACTG-3'; hRARγ , 5'-TGGA-
GACACAGAGCACCAGC-3' and 5'-GTCAGTCTGCT-
GCCTGAAGC-3'; hRXRα , 5'-
CTCCTCAAGCAAGCACTATG-3' and 5'-AGAGCT-
TAGCGAACCTTCCC-3'; hRXRβ , 5'-TCAGGCAAACAC-
TACGGGGT-3' and 5'-GCATACACTTTCTCCCGCAG-3';
hRXRγ , 5'-CTCAGGAAAGCACTACGGGG-3' and 5'-CCG-
GATACTTCTGCTTGGTG-3'; AIB1, 5'-GAGCCGACAG-
GCACTTGAAT-3' and 5'-CCACTGCTGCCATTCATGTG-
3'; CBP, 5'-CGCTCAGATGGGACAGCTTG-3' and 5'-ACT-
TCTCTAGCGTGTCCCCC-3'; p300, 5'-TGGGGTCCCCT-
GTTCAGC-3' and 5'-GTTATCGGTGCTGAGTCCCAGG-3';
p/CIP, 5'-AAGCCCCTCCACAACAGTTT-3' and 5'-CAG-
CAGTATTTCTGATCGGG-3'; RAC3, 5'-CCAGATC-
CAGCCTTTGGTCG-3' and 5'-
ATGCCAGACATGGGCATGGG-3'; RIP140, 5'-
TCAGCCCAGCAGTTGCATGG-3' and 5'-TCCATTT-
GCGCTGTGTGGGC-3'; SRC1, 5'-AATGTGTTCAGT-
CAAGCTGTCCAG-3' and 5'-
TGGTTATTCAGTCAGTAGCTGCTG-3'; TIF1, 5'-CCAAT-
GAGGACTGGTGTGCAG-3' and 5'-GCTTTTGAGGCGTT-
TCTTCCG-3'; TIF2, 5'-CTGAACCAGCATCTTCGAACA-3'
and 5'-ATTTCCGTGTTGTGTCTCCC-3'; TRIP1, 5'-GGCT-
GTGGCTCATCATACGG-3' and 5'-TGAGTGACAT-
GGACTCGCCG-3'; SMRT, 5'-
TGACCTATAGAAGCCAGGC-3' and 5'-GAGAGT-
GTCTCGTACTGCG-3'; N-CoR, 5'-GATCATGGTGTTGT-
CATGTCC-3' and 5'-AGACAGTGTCTCATACTGCGC-3'.
Actin primers were, 5'-ATCATGTTTGAGACCTTCAA-3'
and 5'-CATCTCTTGCTCGAAGTCCA-3'. Linearity was as-
sessed as described above.
Reverse transcription and amplification (RT-PCR) of 
CRABPII and RARβ 2 transcripts in P19 cells
Reverse transcription was performed using oligodT prim-
ers as recommended by the manufacturer (Promega,
Charbonnières, France). Primers were designed as fol-
lows:RARβ  5'-AAGTGGTAGGAAGTGAGCTG-3' and 5'-
CTACATTGAGCAGTATGCCG-3 and CRABPII 5'-CCAG-
GTGGAAGGATCTGTTC-3' and 5'-ATTGGTCAGTTCTCG-
GCTCC-3'. PCR conditions were 40 cycles of 30 sec at
94°C, 1 min at 58°C and 1 min 30 sec at 72°C followed by
an elongation step at 72°C for 7 min (RARβ ) and 30 cycles
of 30 sec at 94°C, 1 min at 56°C and 1 min 30 sec at 72°C
followed by an elongation step at 72°C for 7 min (CRAB-
PII).
Northern Blot analysis
20  µg of total RNA were separated by electrophoresis
through a 1% agarose gel containing 0.62 M formalde-
hyde. RNA was then transferred to a Hybond-N+ mem-
brane (Amersham, Les Ulis, France). Membranes were
probed sequentially with cDNA of interest and an 18S
rRNA probe. Probes were labeled with Fluorescein-dUTP
using the Random Prime labelling module (Amersham,
Les Ulis, France). Prehybridization and overnight hybrid-
ization at 65°C were performed in 5X SSC (1X SSC is 0.15
M NaCl, 15 mM sodium citrate, pH 7), 0.1% SDS, 5%
dextran sulfate and 5% liquid block (Amersham, Les Ulis,
France). After hybridization, membranes were washed at
65°C successively in 2X SSC, 0.1% SDS, 1X SSC, 0.1%
SDS, 0.5X SSC, 0.1% SDS, and 0.1X SSC, 0.1% SDS.
Hybridized probes were revealed using the ECF amplifica-
tion system (Amersham, Les Ulis, France), and visualized
using a Storm™ phosphofluoroimager (Molecular Dy-
namics, Sunnyvale, CA). Bands intensities were quantified
using the ImageQuant™ software (Molecular Dynamics,
Sunnyvale, CA). Values for mRNA of interest were nor-
malized to values for the 18S rRNA.
Real-Time PCR
After purification of RNAs and reverse-transcription as de-
scribed above, the synthesized cDNAs were analyzed by
PCR amplification using the TaqMan PCR master mix
(Applied Biosysytems, Foster City, CA.) and the appropri-BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/13
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ate mix of primers. Typically, a mix of 18S mRARβ  pro-
moter primers was used. 18S primers were purchased
from Applied Biosystems. The FAM/TAMRA probe, for-
ward and reverse primers for the mRARβ  transcript were
CAGCACCGGCATACTGCTCAA, TCAGTGGATTCAC-
CCAGGC (RAR468F) and TCGGGACGAGCTCCTCAG
(RAR557B). Reactions (40 cycles) and data analysis were
carried out on a ABI Prism 7700 (Perkin-Elmer).
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